0001213900-24-027998.txt : 20240329 0001213900-24-027998.hdr.sgml : 20240329 20240329162938 ACCESSION NUMBER: 0001213900-24-027998 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240329 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240329 DATE AS OF CHANGE: 20240329 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TherapeuticsMD, Inc. CENTRAL INDEX KEY: 0000025743 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 870233535 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-00100 FILM NUMBER: 24804410 BUSINESS ADDRESS: STREET 1: 951 YAMATO ROAD, SUITE 220 CITY: BOCA RATON STATE: FL ZIP: 33431 BUSINESS PHONE: 561-961-1900 MAIL ADDRESS: STREET 1: 951 YAMATO ROAD, SUITE 220 CITY: BOCA RATON STATE: FL ZIP: 33431 FORMER COMPANY: FORMER CONFORMED NAME: AMHN, Inc. DATE OF NAME CHANGE: 20090930 FORMER COMPANY: FORMER CONFORMED NAME: CROFF ENTERPRISES INC DATE OF NAME CHANGE: 19970915 FORMER COMPANY: FORMER CONFORMED NAME: CROFF OIL CO DATE OF NAME CHANGE: 19920703 8-K 1 ea0202833-8k_therape.htm CURRENT REPORT
false 0000025743 0000025743 2024-03-29 2024-03-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): March 29, 2024

 

 

 

THERAPEUTICSMD, INC. 

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Nevada   001-00100   87-0233535
(State or Other Jurisdiction
of Incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

951 Yamato Road, Suite 220

Boca Raton, FL 33431

(Address of Principal Executive Office) (Zip Code)

 

Registrant’s telephone number, including area code: (561) 961-1900

 

Not Applicable

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading
Symbol		   Name of Each Exchange
on Which Registered
Common Stock, par value $0.001 per share   TXMD   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230-405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

The information provided in Item 7.01 of this Current Report on Form 8-K is incorporated in this Item 2.02 by reference.

 

Item 7.01 Regulation FD Disclosure.

 

On March 29, 2024, TherapeuticsMD, Inc., a Nevada corporation (the “Company”), issued a press release announcing its financial results for the full year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

The information in this Item 7.01 and the information contained in Exhibit 99.1 is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in any such filing, regardless of any general incorporation language in the filing.

 

The Company does not have, and expressly disclaims, any obligation to release publicly any updates or any changes in its expectations or any change in events, conditions, or circumstances on which any forward-looking statement is based.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit Index

 

Exhibit No.   Description
   
99.1   Press Release from TherapeuticsMD, Inc., dated March 29, 2024, entitled “TherapeuticsMD Announces Full Year 2023 Financial Results”
104   Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: March 29, 2024 THERAPEUTICSMD, INC.
   
  /s/ Marlan Walker
  Marlan Walker
  Chief Executive Officer

 

 

 

2

 

 EX-99.1 2 ea020283301ex99-1_therap.htm PRESS RELEASE FROM THERAPEUTICSMD, INC., DATED MARCH 29, 2024, ENTITLED "THERAPEUTICSMD ANNOUNCES FULL YEAR 2023 FINANCIAL RESULTS"

Exhibit 99.1

 

 

TherapeuticsMD Announces Full Year 2023 Financial Results

 

●Evaluation of strategic alternatives continues

 

BOCA RATON, Fla.--(BUSINESS WIRE)--Mar. 29, 2024-- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023.

 

“We continue to explore a variety of strategic alternatives with the goal of maximizing value for our shareholders,” stated Marlan D. Walker, Chief Executive Officer of TherapeuticsMD.

 

Full Year 2023 Financial Results

 

Net Income (Loss) from Continuing Operations

 

●Net loss from continuing operations was $(7.7) million, or $(0.74) per basic and diluted common share, compared to net income from continuing operations of $1.1 million, or $0.12 per basic and $0.11 per diluted common share, for 2022.

 

License and Service Revenues from Continuing Operations

 

●Gross license royalties totaled approximately $4.5 million under the Mayne License Agreement for the full year ending December 31, 2023. Included in this amount are $3.0 million of gross minimum royalty payments paid under the Mayne License Agreement. The Company recognizes license revenue only on amounts in excess of the gross minimum royalty amounts earned under the Mayne License Agreement. Our net license royalty income is allocated and reported in revenue, net and other income based on the proportion of the sales from each of our licensed products. Based on sales of our licensed products, the Company recognized $1.3 million in revenue, net and approximately $0.5 million in other income in the year ending December 31, 2023 related to net license royalties.

 

Total Operating Expenses from Continuing Operations

 

●Total operating expenses from continuing operations for 2023 were $9.8 million, a decrease of $57.6 million, or 85.4%, compared to 2022, primarily attributable to lower general and administrative expenses due to the transition of the Company’s business from a commercializing pharmaceutical business to a royalty-based business.

 

Evaluation of Strategic Alternatives

 

●The Company continues to evaluate a variety of strategic alternatives that may include, but not be limited to, an acquisition, merger, other business combination, sale of assets, or other strategic transactions involving the Company. Although the Company is exploring potential strategic alternatives, there can be no assurance of a transaction, a successful outcome of these efforts, or the form or timing of any such outcome. The Company has not set a timetable for completion of this exploration process and does not intend to disclose further developments unless and until it is determined that disclosure is appropriate or necessary.

 

 

 

 

Balance Sheet

 

●As of December 31, 2023, the Company’s cash and cash equivalents totaled $4.3 million.

 

About TherapeuticsMD

 

TherapeuticsMD was previously a women’s healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause. In December 2022, the Company changed its business to become a pharmaceutical royalty company, primarily collecting royalties from its licensees. The Company is no longer engaging in research and development or commercial operations.

 

Forward-Looking Statements

 

This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies, including the exploration of potential strategic alternatives that may include, but are not limited to, an acquisition, merger, other business combination, sale of assets, or other strategic transactions, and the completion of such a review process as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: whether the company’s licensees will be successful at commercializing the products that they licensed and acquired from TherapeuticsMD; whether the company is successful in winding down its operations and the costs associated therewith, including the company’s ability to obtain any additional financing necessary therefor and any adjustments to the net working capital purchased as part of the Mayne Pharma transaction; whether the company is successful in identifying strategic pathways to create additional shareholder value; the company’s ability to remain listed on Nasdaq; the impact of product liability lawsuits; the impact of leadership transitions; and the volatility of the trading price of the company’s common stock.

 

Marlan D. Walker
Chief Executive Officer
561-961-1900
IR@TherapeuticsMD.com

 

Lisa M. Wilson
In-Site Communications, Inc.
212-452-2793
lwilson@insitecony.com

 

Source: TherapeuticsMD, Inc.

 

 

 

 

 

 EX-101.SCH 3 txmd-20240329.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 txmd-20240329_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 txmd-20240329_pre.xml XBRL PRESENTATION FILE GRAPHIC 6 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Cover
Mar. 29, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 29, 2024
Entity File Number 001-00100
Entity Registrant Name THERAPEUTICSMD, INC.
Entity Central Index Key 0000025743
Entity Tax Identification Number 87-0233535
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 951 Yamato Road
Entity Address, Address Line Two Suite 220
Entity Address, City or Town Boca Raton
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33431
City Area Code 561
Local Phone Number 961-1900
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol TXMD
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://therapeuticsmd.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea0202833-8k_therape.htm txmd-20240329.xsd txmd-20240329_lab.xml txmd-20240329_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0202833-8k_therape.htm": { "nsprefix": "TXMD", "nsuri": "http://therapeuticsmd.com/20240329", "dts": { "inline": { "local": [ "ea0202833-8k_therape.htm" ] }, "schema": { "local": [ "txmd-20240329.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "txmd-20240329_lab.xml" ] }, "presentationLink": { "local": [ "txmd-20240329_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://therapeuticsmd.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-29", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0202833-8k_therape.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-29", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0202833-8k_therape.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://therapeuticsmd.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001213900-24-027998-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-027998-xbrl.zip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end XML 18 ea0202833-8k_therape_htm.xml IDEA: XBRL DOCUMENT 0000025743 2024-03-29 2024-03-29 iso4217:USD shares iso4217:USD shares false 0000025743 8-K 2024-03-29 THERAPEUTICSMD, INC. NV 001-00100 87-0233535 951 Yamato Road Suite 220 Boca Raton FL 33431 561 961-1900 false false false false Common Stock, par value $0.001 per share TXMD NASDAQ false